Head to Head Analysis: Treace Medical Concepts (NASDAQ:TMCI) & Coloplast A/S (OTCMKTS:CLPBY)

Treace Medical Concepts (NASDAQ:TMCI) and Coloplast A/S (OTCMKTS:CLPBY) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, institutional ownership, profitability, analyst recommendations and valuation.

Earnings and Valuation

This table compares Treace Medical Concepts and Coloplast A/S”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Treace Medical Concepts	$212.69 million	1.46	-$59.00 million	($0.86)	-5.56
Coloplast A/S	$4.50 billion	3.79	$538.49 million	$0.21	36.00

Coloplast A/S has higher revenue and earnings than Treace Medical Concepts. Treace Medical Concepts is trading at a lower price-to-earnings ratio than Coloplast A/S, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for Treace Medical Concepts and Coloplast A/S, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Treace Medical Concepts	1	1	3	0	2.40
Coloplast A/S	1	1	0	2	2.75

Treace Medical Concepts presently has a consensus target price of $6.17, suggesting a potential upside of 29.01%. Given Treace Medical Concepts’ higher possible upside, analysts plainly believe Treace Medical Concepts is more favorable than Coloplast A/S.

Profitability

This table compares Treace Medical Concepts and Coloplast A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Treace Medical Concepts	-28.99%	-71.37%	-30.49%
Coloplast A/S	10.57%	42.25%	11.87%

Insider and Institutional Ownership

84.1% of Treace Medical Concepts shares are held by institutional investors. 23.4% of Treace Medical Concepts shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Volatility and Risk

Treace Medical Concepts has a beta of 1.59, suggesting that its stock price is 59% more volatile than the S&P 500. Comparatively, Coloplast A/S has a beta of 0.1, suggesting that its stock price is 90% less volatile than the S&P 500.

Summary

Coloplast A/S beats Treace Medical Concepts on 10 of the 15 factors compared between the two stocks.

About Treace Medical Concepts

Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.

About Coloplast A/S

Coloplast A/S engages in the development and sale of intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Continence Care, Voice and Respiratory Care, Interventional Urology, and Advanced Wound Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen Plus, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, and hand cleansers, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, its voice and respiratory care solutions include laryngectomy care products comprising Provox, a voice prosthesis for speaking, HMEs, adhesives, laryngectomy tubes for breathing, devices for speaking hands-free, and accessories, as well as tracheostomy care products under Tracoe brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.